FI970310A0 - 4-indolijohdannaiset serotoniinin vaikuttaja- ja vastavaikuttaja-aineina - Google Patents

4-indolijohdannaiset serotoniinin vaikuttaja- ja vastavaikuttaja-aineina

Info

Publication number
FI970310A0
FI970310A0 FI970310A FI970310A FI970310A0 FI 970310 A0 FI970310 A0 FI 970310A0 FI 970310 A FI970310 A FI 970310A FI 970310 A FI970310 A FI 970310A FI 970310 A0 FI970310 A0 FI 970310A0
Authority
FI
Finland
Prior art keywords
antagonists
indole derivatives
serotonin agonists
serotonin
agonists
Prior art date
Application number
FI970310A
Other languages
English (en)
Swedish (sv)
Other versions
FI970310A (fi
Inventor
John Eugene Macor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI970310A0 publication Critical patent/FI970310A0/fi
Publication of FI970310A publication Critical patent/FI970310A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI970310A 1994-07-26 1997-01-24 4-indolijohdannaiset serotoniinin vaikuttaja- ja vastavaikuttaja-aineina FI970310A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28119294A 1994-07-26 1994-07-26
PCT/IB1995/000335 WO1996003400A1 (en) 1994-07-26 1995-05-08 4-indole derivatives as serotonin agonists and antagonists

Publications (2)

Publication Number Publication Date
FI970310A0 true FI970310A0 (fi) 1997-01-24
FI970310A FI970310A (fi) 1997-01-24

Family

ID=23076331

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970310A FI970310A (fi) 1994-07-26 1997-01-24 4-indolijohdannaiset serotoniinin vaikuttaja- ja vastavaikuttaja-aineina

Country Status (7)

Country Link
US (1) US6255306B1 (fi)
EP (1) EP0773942A1 (fi)
JP (1) JP3155008B2 (fi)
CA (1) CA2194984C (fi)
FI (1) FI970310A (fi)
MX (1) MX9700693A (fi)
WO (1) WO1996003400A1 (fi)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9700693A (es) * 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
GB9514384D0 (en) * 1995-07-13 1995-09-13 American Home Prod Medical treatment
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
WO1999052539A1 (en) 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophan
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
CA2414938A1 (en) * 2000-07-06 2002-01-17 Simon Nicholas Jenkins Combinations of ssri and estrogenic agents
EP1656938A1 (en) * 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
DE60128475T2 (de) 2000-07-25 2008-02-07 Merck & Co., Inc. N-substituierte indole mit anwendung in der behandlung von diabetes
MXPA03003397A (es) 2000-10-20 2004-06-30 Biovitrum Ab N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia.
AU2005102A (en) * 2000-11-02 2002-05-15 Wyeth Corp 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
ATE337780T1 (de) * 2000-11-24 2006-09-15 Smithkline Beecham Plc Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE10121217A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
EP1401813B1 (en) 2001-06-07 2007-02-07 F. Hoffman-la Roche AG New indole derivatives with 5-ht6 receptor affinity
CA2450245A1 (en) 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
MXPA04000036A (es) 2001-07-05 2004-05-21 Upjohn Co Benzofuranos sustituidos con (hetero) arilo como ligandos 5-ht.
EP1476151B1 (en) * 2002-02-12 2008-07-16 N.V. Organon 1-arylsulfonyl-3-substitued indole and indoline derivates useful in the treatment of central nervous system disorders
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
FR2841547B1 (fr) * 2002-06-26 2005-05-06 Rhodia Elect & Catalysis Composition a base d'oxyde de zirconium et d'oxydes de cerium, de lanthane et d'une autre terre rare, son procede de preparation et son utilisation comme catalyseur
US7087575B2 (en) 2002-07-18 2006-08-08 Mayo Foundation For Medical Education And Research Treating the effect of nicotine
KR100686757B1 (ko) * 2002-09-17 2007-02-26 에프. 호프만-라 로슈 아게 2,4-치환된 인돌 및 그의 5-ｈｔ6 조절제로서 용도
ATE362469T1 (de) 2002-09-17 2007-06-15 Hoffmann La Roche 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
DK1581492T3 (da) * 2002-11-28 2008-11-10 Suven Life Sciences Ltd N-arylsulfonyl-3-substituerede indoler med serotoninreceptoraffinitet, fremgangsmåde til fremstilling heraf og en farmaceutisk sammensætning indeholdende disse
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
US20050250803A1 (en) * 2003-11-26 2005-11-10 Pfizer Inc Combination of dopamine agonists and monoamine reuptake inhibitors
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007057329A1 (en) * 2005-11-18 2007-05-24 F. Hoffmann-La Roche Ag Azaindole-2-carboxamide derivatives
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
CA2637531A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
WO2007100718A2 (en) 2006-02-24 2007-09-07 Denise Barbut Neurotensin receptor agonists and opioid receptor agonists
WO2007100066A1 (ja) * 2006-03-02 2007-09-07 Astellas Pharma Inc. １７βＨＳＤｔｙｐｅ５阻害剤
RU2449990C2 (ru) 2006-07-03 2012-05-10 Биовитрум Аб (Пабл) Индолы в качестве модуляторов 5-ht6
BRPI0718776A2 (pt) 2006-11-09 2013-12-03 Hoffmann La Roche Derivados de indol e benzofurano 2-carboxamida
US8138333B2 (en) 2007-03-13 2012-03-20 Proximagen Limited Sulfonyl-indole derivatives
KR20100053626A (ko) * 2007-08-15 2010-05-20 메모리 파마슈티칼스 코포레이션 5-ｈｔ6 수용체 친화성을 나타내는 3'-치환된 화합물
ES2523580T3 (es) 2008-01-11 2014-11-27 Albany Molecular Research, Inc. Piridoindoles substituidos con (1-Azinona)
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
JP2012532144A (ja) * 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
PL395469A1 (pl) * 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
US11807644B2 (en) * 2020-05-12 2023-11-07 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2056435A (en) * 1979-06-26 1981-03-18 Ciba Geigy Ag Novel Tetrahydropyridine and Piperidine Substituted Benzofuranes and Related Compounds
CH653021A5 (fr) * 1981-04-24 1985-12-13 Delalande Sa Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
FR2510111A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
DE3571436D1 (en) * 1984-12-21 1989-08-17 Duphar Int Res New pharmaceutical compositions having anti-psychotic properties
ATE81975T1 (de) * 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
AU646871B2 (en) * 1990-06-07 1994-03-10 Astrazeneca Uk Limited Therapeutic heterocyclic compounds
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
KR940007001A (ko) * 1992-09-16 1994-04-26 최승주 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
GB9300195D0 (en) * 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9308725D0 (en) * 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
GB9411099D0 (en) * 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
MX9700693A (es) * 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.

Also Published As

Publication number Publication date
EP0773942A1 (en) 1997-05-21
JP3155008B2 (ja) 2001-04-09
FI970310A (fi) 1997-01-24
CA2194984A1 (en) 1996-02-08
US6255306B1 (en) 2001-07-03
MX9700693A (es) 1997-04-30
CA2194984C (en) 2002-07-02
JPH09508137A (ja) 1997-08-19
WO1996003400A1 (en) 1996-02-08

Similar Documents

Publication Publication Date Title
FI970310A0 (fi) 4-indolijohdannaiset serotoniinin vaikuttaja- ja vastavaikuttaja-aineina
DK0516349T3 (da) 2-hydroxy-2-phenylethylamin-derivater som beta-3-adrenoceptoragonister
FI964576A0 (fi) Uusia agonistiyhdisteitä
NO940974L (no) Benzanilid-derivater som 5-HT1D antagonister
FI944805A (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina
NO943762L (no) Indolderivater som 5-HT 1 agonister
ITMI941466A0 (it) Uso di derivati di chinolina
DE69605430D1 (de) Chinolin-2-on derivate als serotonin antagonisten
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
IS4800A (is) Nýjar 19-nor-pregnene afleiður
FI961628A (fi) Indolijohdannaisia NMDA-antagonisteina
NO963117D0 (no) Indol-derivater som 5-HT1-agonister
DK0922034T3 (da) Tetrahydroquinolinderivater som EAA-antagonister
NO974043D0 (no) Indolderivater som EAA-antagonister
DE69506826D1 (de) 5-HT4 Rezeptoragonisten
NO954287L (no) Anvendelse av indolderivater som 5-HT1 agonister
NO963331D0 (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
NO985970L (no) Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister
FI951798A0 (fi) Bentsofuraanijohdannaiset 5-HT1-kaltaisina reseptoriantagonisteina
FI961977A0 (fi) N-substituoidut atsabisykloalkaanijohdannaiset, niiden valmistus ja käyttö
FI941984A0 (fi) Tudelat badkar foer saovael medicinska och naturmedicinska behandlingsbad som rekreationsbad
ITMI941099A0 (it) Derivati chinolinici
DE69320653D1 (de) Tetrahydrocarbazolderivate als 5-ht1-ähnliche agonisten
DK0944601T3 (da) Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister
FI960084A (fi) Piperidinyylillä substituoidut metanoantraseenit D1/D2-antagonisteina ja 5HT2-serotoniiniantagonisteina

Legal Events

Date Code Title Description
MA Patent expired